TY - JOUR
T1 - Evaluation of the prebiotic potential of arabinoxylans from brewer’s spent grain
AU - Reis, Sofia F.
AU - Gullón, Beatriz
AU - Gullón, Patricia
AU - Ferreira, Susana
AU - Maia, Cláudio J.
AU - Alonso, José L.
AU - Domingues, Fernanda C.
AU - Abu-Ghannam, Nissreen
N1 - Funding Information:
Acknowledgments The authors wish to acknowledge the Irish Department of Agriculture, Food and the Marine for their funding of this project (No. 08RDTAFRC665) under the Food Institutional Research Measure (FIRM). B. Gullón and P. Gullón are grateful to Fundação para a Ciência e Tecnologia (FCT) for the postdoctoral fellowships references SFRH/BPD/79941/2011 and SFRH/BPD/79942/2011. S. Ferreira was supported by FCT with the fellowship reference SFRH/BD/66857/2009 and co-financed by Fundo Social Europeu (FSE). Authors are also grateful to Xunta de Galicia for the financial support of this work (INBIOMED project), partially funded by FEDER “Unha maneira de facer Europa”.
Publisher Copyright:
© 2014, Springer-Verlag Berlin Heidelberg.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014/11
Y1 - 2014/11
N2 - Arabinoxylans (AX) consumption has been related to the treatment and prevention of cardiovascular diseases, type II diabetes, colorectal cancer and obesity. The beneficial health effects are conferred through gut microbiota modulation, and therefore, they have been proposed as potential slowly fermentable prebiotic candidates. As the mechanisms are not yet well understood, the prebiotic potential of AX from brewer’s spent grain (BSG) has been investigated. Two types of AX from BSG (AX1 and AX2) of different length and branching averages were fermented with human faecal inocula and compared to fermented cultures containing a commercial prebiotic (fructooligosaccharide (FOS)) and cultures with no added carbohydrate (control). Results demonstrated that the AX were extensively metabolised after 48 h of fermentation. The pH decreased along fermentation and the lowest value was achieved in AX1 cultures. The production of short chain fatty acids (SCFA) was higher in AX cultures than in cultures containing FOS and controls, with AX1 presenting the highest concentrations. The stimulatory effect of beneficial bacteria was higher in AX cultures, and AX2 presented the highest positive effect. Prebiotic potential of AX from BSG was confirmed by the production of SCFA and the modulation of gut microbiota, especially by the high increase in bifidobacteria populations.
AB - Arabinoxylans (AX) consumption has been related to the treatment and prevention of cardiovascular diseases, type II diabetes, colorectal cancer and obesity. The beneficial health effects are conferred through gut microbiota modulation, and therefore, they have been proposed as potential slowly fermentable prebiotic candidates. As the mechanisms are not yet well understood, the prebiotic potential of AX from brewer’s spent grain (BSG) has been investigated. Two types of AX from BSG (AX1 and AX2) of different length and branching averages were fermented with human faecal inocula and compared to fermented cultures containing a commercial prebiotic (fructooligosaccharide (FOS)) and cultures with no added carbohydrate (control). Results demonstrated that the AX were extensively metabolised after 48 h of fermentation. The pH decreased along fermentation and the lowest value was achieved in AX1 cultures. The production of short chain fatty acids (SCFA) was higher in AX cultures than in cultures containing FOS and controls, with AX1 presenting the highest concentrations. The stimulatory effect of beneficial bacteria was higher in AX cultures, and AX2 presented the highest positive effect. Prebiotic potential of AX from BSG was confirmed by the production of SCFA and the modulation of gut microbiota, especially by the high increase in bifidobacteria populations.
KW - Arabinoxylans
KW - Brewer’s spent grain
KW - Intestinal microbiota
KW - Prebiotics
KW - qPCR
KW - Short chain fatty acids
UR - http://www.scopus.com/inward/record.url?scp=84919898169&partnerID=8YFLogxK
U2 - 10.1007/s00253-014-6009-8
DO - 10.1007/s00253-014-6009-8
M3 - Article
C2 - 25117549
AN - SCOPUS:84919898169
SN - 0175-7598
VL - 98
SP - 9365
EP - 9373
JO - Applied Microbiology and Biotechnology
JF - Applied Microbiology and Biotechnology
IS - 22
ER -